Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 15/20 | 0.43 |
| ▸ | GJB2 | P29033 | 1/20 | 0.42 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.41 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.41 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.41 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.41 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 6/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.38 |
| ▸ | CDC25B | P30305 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1647905 | 0.91 | GJB2 (0.50) | NT5EPTPN1GJB2SSTR1SSTR2 | |
| SCHEMBL1647584 | 0.87 | SSTR1 (0.45) | NT5EPTPN1GJB2SSTR1SSTR2 | |
| SCHEMBL21233296 | 0.81 | NT5E (0.51) | NT5EPTPN1GJB2SSTR1SSTR2 | |
| SCHEMBL13058736 | 0.81 | NT5E (0.54) | NT5EPTPN1SSTR1SSTR2SSTR4 | |
| SCHEMBL14428921 | 0.81 | NT5E (0.63) | NT5EPTPN1SSTR1SSTR2SSTR4 | |
| SCHEMBL22677692 | 0.78 | SSTR1 (0.57) | NT5EPTPN1GJB2SSTR1SSTR2 | |
| SCHEMBL22678415 | 0.78 | SSTR1 (0.57) | NT5EPTPN1GJB2SSTR1SSTR2 | |
| SCHEMBL22677699 | 0.78 | SSTR1 (0.57) | NT5EPTPN1GJB2SSTR1SSTR2 | |
| SCHEMBL8331303 | 0.78 | NT5E (0.55) | NT5EPTPN1GJB2SSTR1SSTR2 | |
| SCHEMBL8468516 | 0.78 | NT5E (0.55) | NT5EPTPN1GJB2SSTR1SSTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919614-B2 | Disaccharide sequences formed by uronic acid and hexose as to form polysaccharides of 8-24 monosaccharide units whose hydroxyl groups are substituted by alkyl or sulphate groups; possible to modulate activities of glycosaminoglycans type | SANOFI-AVENTIS (FR) | 2011-04-05 | — | — | US | disclosed |
| US-20040068108-A1 | Synthetic polysaccharides, process for their preparation and pharmaceutical compositions containing them | SANOFI-SYNTHELABO (FR) | 2004-04-08 | — | — | US | disclosed |
| EP-0904299-B1 | SYNTHETIC POLYSACCHARIDES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID POLYSACCHARIDES | SANOFI SYNTHELABO (FR) | 2001-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040068108-A1 | Synthetic polysaccharides, process for their preparation and pharmaceutical compositions containing them | UGGT1, GALE, UGDH | NT5E 2648/4885PTPN1 1990/4885GJB2 4802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.